These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 15458371)
1. Lung cancer-related genes in the blood. Sonobe M; Tanaka F; Wada H Ann Thorac Cardiovasc Surg; 2004 Aug; 10(4):213-7. PubMed ID: 15458371 [TBL] [Abstract][Full Text] [Related]
2. Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up? Bremnes RM; Sirera R; Camps C Lung Cancer; 2005 Jul; 49(1):1-12. PubMed ID: 15949585 [TBL] [Abstract][Full Text] [Related]
3. Circulating DNA and lung cancer. Xue X; Zhu YM; Woll PJ Ann N Y Acad Sci; 2006 Sep; 1075():154-64. PubMed ID: 17108206 [TBL] [Abstract][Full Text] [Related]
4. Circulating free tumor DNA and colorectal cancer. Lecomte T; Ceze N; Dorval E; Laurent-Puig P Gastroenterol Clin Biol; 2010 Dec; 34(12):662-81. PubMed ID: 20832215 [TBL] [Abstract][Full Text] [Related]
5. Microsatellite analysis of induced sputum DNA in patients with lung cancer in heavy smokers and in healthy subjects. Castagnaro A; Marangio E; Verduri A; Chetta A; D'Ippolito R; Del Donno M; Olivieri D; Di Cola G Exp Lung Res; 2007 Aug; 33(6):289-301. PubMed ID: 17694439 [TBL] [Abstract][Full Text] [Related]
6. Prognosis of non-small cell lung cancer patients by detecting circulating cancer cells in the peripheral blood with multiple marker genes. Sher YP; Shih JY; Yang PC; Roffler SR; Chu YW; Wu CW; Yu CL; Peck K Clin Cancer Res; 2005 Jan; 11(1):173-9. PubMed ID: 15671543 [TBL] [Abstract][Full Text] [Related]
7. Aberrant promoter hypermethylation in serum DNA from patients with silicosis. Umemura S; Fujimoto N; Hiraki A; Gemba K; Takigawa N; Fujiwara K; Fujii M; Umemura H; Satoh M; Tabata M; Ueoka H; Kiura K; Kishimoto T; Tanimoto M Carcinogenesis; 2008 Sep; 29(9):1845-9. PubMed ID: 18632757 [TBL] [Abstract][Full Text] [Related]
8. The early detection of occult lung cancer. Tockman MS; Mulshine JL Chest Surg Clin N Am; 2000 Nov; 10(4):737-49. PubMed ID: 11091923 [TBL] [Abstract][Full Text] [Related]
9. Molecular diagnostic markers for lung cancer in sputum and plasma. Wang YC; Hsu HS; Chen TP; Chen JT Ann N Y Acad Sci; 2006 Sep; 1075():179-84. PubMed ID: 17108209 [TBL] [Abstract][Full Text] [Related]
10. Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma. Hsu HS; Chen TP; Hung CH; Wen CK; Lin RK; Lee HC; Wang YC Cancer; 2007 Nov; 110(9):2019-26. PubMed ID: 17876837 [TBL] [Abstract][Full Text] [Related]
11. Methylation of RAS association domain family protein 1A as a biomarker of lung cancer. Grote HJ; Schmiemann V; Geddert H; Bocking A; Kappes R; Gabbert HE; Sarbia M Cancer; 2006 Apr; 108(2):129-34. PubMed ID: 16444703 [TBL] [Abstract][Full Text] [Related]
12. Free circulating nucleic acids in plasma and serum (CNAPS) -- Useful for the detection of lung cancer patients? Fleischhacker M; Schmidt B Cancer Biomark; 2010; 6(3-4):211-9. PubMed ID: 20660966 [TBL] [Abstract][Full Text] [Related]
13. Detection of promoter hypermethylation in serum samples of cancer patients by methylation-specific polymerase chain reaction for tumour suppressor genes including RUNX3. Tan SH; Ida H; Lau QC; Goh BC; Chieng WS; Loh M; Ito Y Oncol Rep; 2007 Nov; 18(5):1225-30. PubMed ID: 17914577 [TBL] [Abstract][Full Text] [Related]
14. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. Hoque MO; Topaloglu O; Begum S; Henrique R; Rosenbaum E; Van Criekinge W; Westra WH; Sidransky D J Clin Oncol; 2005 Sep; 23(27):6569-75. PubMed ID: 16170165 [TBL] [Abstract][Full Text] [Related]
15. Frequent inactivation of RASSF1A, BLU, and SEMA3B on 3p21.3 by promoter hypermethylation and allele loss in non-small cell lung cancer. Ito M; Ito G; Kondo M; Uchiyama M; Fukui T; Mori S; Yoshioka H; Ueda Y; Shimokata K; Sekido Y Cancer Lett; 2005 Jul; 225(1):131-9. PubMed ID: 15922865 [TBL] [Abstract][Full Text] [Related]
16. Promoter hypermethylation is the predominant mechanism in hMLH1 and hMSH2 deregulation and is a poor prognostic factor in nonsmoking lung cancer. Hsu HS; Wen CK; Tang YA; Lin RK; Li WY; Hsu WH; Wang YC Clin Cancer Res; 2005 Aug; 11(15):5410-6. PubMed ID: 16061855 [TBL] [Abstract][Full Text] [Related]
17. Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer. Paci M; Maramotti S; Bellesia E; Formisano D; Albertazzi L; Ricchetti T; Ferrari G; Annessi V; Lasagni D; Carbonelli C; De Franco S; Brini M; Sgarbi G; Lodi R Lung Cancer; 2009 Apr; 64(1):92-7. PubMed ID: 18804892 [TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of mesenteric and peripheral blood circulating tumor DNA in colorectal cancer patients. Taback B; Saha S; Hoon DS Ann N Y Acad Sci; 2006 Sep; 1075():197-203. PubMed ID: 17108212 [TBL] [Abstract][Full Text] [Related]
19. Can aberrant promoter hypermethylation of CpG islands predict the clinical outcome of non-small cell lung cancer after curative resection? Kim YT; Lee SH; Sung SW; Kim JH Ann Thorac Surg; 2005 Apr; 79(4):1180-8; discussion 1180-8. PubMed ID: 15797047 [TBL] [Abstract][Full Text] [Related]
20. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. Hoque MO; Begum S; Topaloglu O; Chatterjee A; Rosenbaum E; Van Criekinge W; Westra WH; Schoenberg M; Zahurak M; Goodman SN; Sidransky D J Natl Cancer Inst; 2006 Jul; 98(14):996-1004. PubMed ID: 16849682 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]